Cullinan oncology announces phase 1/2a interim data for cullinan pearl's cln-081 in nsclc egfr exon 20 patients

Cambridge, mass., june 04, 2021 (globe newswire) -- cullinan oncology, inc. (nasdaq: cgem) (“cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced additional details pertaining to cullinan pearl's ongoing phase 1/2a trial of cln-081 in non-small cell lung cancer (nsclc) patients whose tumors harbor epidermal growth factor receptor (egfr) exon 20 insertion mutations. cln-081 is an orally available, irreversible egfr inhibitor, utilizing a unique pyrrolopyrimidine scaffold that was designed to selectively target cells expressing mutant egfr variants, including exon 20, while sparing cells expressing wild type (wt) egfr.
CGEM Ratings Summary
CGEM Quant Ranking